This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.
West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.
Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
Buy XOM, SLCA, CNC and R Before Earnings Reports?
by Sejuti Banerjea
The earnings season is coming in soft as expected, but there should be a boost from energy stocks later this week.
Centene (CNC) Q1 Earnings Beat Estimates, Ups '22 EPS View
by Zacks Equity Research
Centene's (CNC) first-quarter results highlight improved premium and service revenues and, higher membership growth. An increased 2022 guidance with respect to EPS and revenues should impress investors.
Centene (CNC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 8.93% and 7.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCV
What to Expect From Centene (CNC) this Earnings Season?
by Zacks Equity Research
Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.
Cigna (CI) Evernorth Business Ties Up With Kaiser Permanente
by Zacks Equity Research
Cigna (CI) arm Evernorth partners with integrated health care organization Kaiser Permanente to offer better care to Kaiser members.
Anthem (ANTM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Anthem (ANTM) delivered earnings and revenue surprises of 5.63% and 1.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth
by Zacks Equity Research
Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.
Why Holding Centene (CNC) in Your Portfolio is a Smart Move
by Zacks Equity Research
Banking on a robust portfolio, buyouts and alliances plus contract wins, Centene (CNC) holds prospects to reap benefits for investors.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Centene (CNC) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC) Wins Contract to Serve Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) Indiana subsidiary receives a contract from the Indiana Department of Administration, thereby continuing to serve the unique health needs of Indiana communities.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Should Value Investors Consider Centene (CNC) Stock Now?
by Zacks Equity Research
Let's see if Centene Corporation (CNC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Select Medical (SEM) Q4 Earnings Beat on Higher Admissions
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results reflect solid revenues driven by robust contributions from all its segments, partly offset by higher costs and expenses.
Teladoc (TDOC) Unveils Solution to Ease Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches Chronic Care Complete for extending a comprehensive suite of chronic condition management services for serving the whole-person health needs of eligible members.